This is primarily the reason why I am in ARIA - like you, I think the T315I population alone would justify ARIA's current market cap. Any additional indications for ponatinib, or success of ridaforolimus (I'm not pinning much hope on significant revenues in sarcoma) or '113 would be a bonus.
Market Data 
Markets 
AI
